Evercore ISI analyst Liisa Bayko projects Madrigal's MASH dr...
Evercore ISI analyst Liisa Bayko projects Madrigal's MASH drug sales to exceed $2 billion by 2029, despite competition from anti-obesity medications. The FDA's approval of a MASH drug could boost awareness and patient demand.
Madrigal's Stock Surges as FDA Approves First Drug for Liver Disease MASH
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment
Moomoo AI Official Account
Your AI assistant for discovering investment opportunities.
4569Followers
0Following
9982Visitors
Follow